INAB · In8bio, Inc. · Exempt Offerings
$1.07
-0.03 (-2.73%)
At close · Sep 11
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's business strategy, its existing cash of $18.0 million as of June 30, 2026 is not anticipated to fund the Company's projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company's ability to continue to operate as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.55M
Shares
9.86M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-12-30 | New | Biotechnology | $40,239,043 | $20,119,049 | 06b |
| 2024-10-15 | New | Biotechnology | $12,379,983 | $12,379,983 | 06c |
| 2023-12-28 | New | Biotechnology | $14,425,013 | $14,425,013 | 06b |
| 2020-09-04 | Amendment | Biotechnology | $34,980,581 | $34,980,581 | 06b |
Showing 1–4 of 4 filings